drugset / Trial / NCT00528645

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00528645

Phase 2 Completed 23 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.

Timeline

Start
2007-11
Primary completion
2008-11
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject saracatinib Small molecule Oral